Skip Navigation

Pheochromocytoma and Paraganglioma: Scientific Articles

Skip sharing on social media links

Featured Articles

The following featured articles include those from NICHD researchers or NICHD-supported researchers:

  • Giubellino, A., Bullova, P., Nolting, S., Turkova, H., Powers, J. F., Liu, Q. et al. (2013). Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: In vitro and in vivo studies in female athymic nude mice. Endocrinology, 154(2),646–655. PMID: 23307788
  • Giubellino, A., Sourbier, C., Lee, M. J., Scroggins, B., Bullova, P., Landau, M. et al. (2013). Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PLoS One, 8(2),e56083. PMID: 23457505
  • Matro, J., Giubellino, A., & Pacak, K. (2013). Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: Focus on SDHB tumors. Hormone and Metabolic Research, 45(2),147–153. PMID: 23322515
  • Pacak, K., Jochmanova, I., Prodanov, T., Yang, C., Merino, M. J., Fojo, T., et al. (2013). New syndrome of paraganglioma and somatostatinoma associated with polycythemia. Journal of Clinical Oncology, 31(13),1690–1698. PMID: 23509317
  • Taïeb, D., Yang, C., Delenne, B., Zhuang, Z., Barlier, A., Sebag, F., et al. (2013). First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome. Journal of Clinical Endocrinology and Metabolism, 98(5),E908–E913. PMID: 23539726
  • Vicha, A., Musil, Z., & Pacak, K. (2013). Genetics of pheochromocytoma and paraganglioma syndromes: New advances and future treatment options. Current Opinion in Endocrinology, Diabetes, and Obesity, 20(3),186–191. PMID: 23480210
  • Eisenhofer, G., Lenders, J. W., Siegert, G., Bornstein, S. R., Friberg, P., Milosevic, D., et al. (2012). Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. European Journal of Cancer, 48(11), 1739–1749. PMID: 22036874
  • Fonte, J. S., Robles, J. F., Chen, C. C., Reynolds, J., Whatley, M., Ling, A., et al. (2012). False-negative I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocrine-Related Cancer, 19(1), 83–93. PMID: 22167067
  • Giubellino, A., Woldemichael, G. M., Sourbier, C., Lizak, M. J., Powers, J. F., Tischler, A. S., et al. (2012). Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. Cancer Letters, 316(1),46–52. PMID: 22154086
  • Shah, U., Giubellino, A., & Pacak, K. (2012). Pheochromocytoma: Implications in tumorigenesis and the actual management. Minerva Endocrinologica, 37(2), 141–156. PMID: 22691888
  • Zhuang, Z., Yang, C., Lorenzo, F., Merino, M., Fojo, T., Kebebew, E., et al. (2012). Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. New England Journal of Medicine, 367(10),922–930. PMID: 22931260
  • Eisenhofer, G., Lenders, J. W., Timmers, H., Mannelli, M., Grebe, S. K., Hofbauer, L. C., et al. (2011). Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clinical Chemistry, 57, 411–420. PMID: 21262951
  • King, K. S., Prodanov, T., Kantorovich, V., Fojo, T., Hewitt, J. K., Zacharin, M., et al. (2011). Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: Significant link to SDHB mutations. Journal of Clinical Oncology, 29, 4137–4142. PMID: 21969497

PubMed Search Results

Use the links below to search the PubMed database of more than 20 million citations for scientific articles.

BOND National Institues of Health Home Home Division of Intramural Population Health Research